Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Blueprint Medicines Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Blueprint Medicines Corp, Medical Devices Deals, 2012 to YTD 2018 10
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Blueprint Medicines Raises USD50 Million in Series C Venture Financing 13
Blueprint Medicines Raises US$25 Million In Series B Venture Financing 16
Blueprint Medicines Raises US$40 Million In Series A Venture Financing 18
Partnerships 20
Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 20
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 21
Licensing Agreements 22
CStone Pharma Enters into Licensing Agreement with Blueprint Medicines 22
Roche Enters into Licensing Agreement with Blueprint Medicines 24
Equity Offering 26
Blueprint Medicines Raises USD325.5 Million in Public Offering of Shares 26
Blueprint Medicines Raises USD230 Million in Public Offering of Shares 28
Blueprint Medicines Raises USD143.8 Million in Public Offering of Shares 30
Blueprint Medicines Completes IPO 32
Blueprint Medicines Corp – Key Competitors 34
Blueprint Medicines Corp – Key Employees 35
Blueprint Medicines Corp – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 01, 2018: Blueprint medicines reports second quarter 2018 financial results 37
May 02, 2018: Blueprint Medicines Reports First Quarter 2018 Financial Results 39
Feb 21, 2018: Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results 41
Oct 31, 2017: Blueprint Medicines Reports Third Quarter 2017 Financial Results 43
Aug 02, 2017: Blueprint Medicines Reports Second Quarter 2017 Financial Results 45
May 03, 2017: Blueprint Medicines Reports First Quarter 2017 Financial Results 46
Mar 09, 2017: Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results 48
Research And Development 50
Jul 27, 2017: Blueprint Medicines to Evaluate Opportunities to Advance Rare Disease Discovery Program in Fibrodysplasia Ossificans Progressiva Following Discontinuation of Collaboration with Alexion 50
Corporate Communications 51
Oct 10, 2017: Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations 51
Product News 52
04/15/2018: Selective Inhibitor Shows Early Promise in Patients With RET-altered Cancers 52
03/27/2017: Blueprint Medicines to Present on BLU-285 at Upcoming Scientific Conferences 53
03/27/2017: Blueprint Medicines to Present on BLU-554 at Upcoming Scientific Conferences 54
Clinical Trials 55
Jun 21, 2018: Blueprint doses first patient in Voyager trial 55
Jun 15, 2018: Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity 56
May 17, 2018: Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis 59
Apr 15, 2018: Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors 60
Apr 15, 2018: Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 62
Mar 14, 2018: Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018 63
Dec 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity 64
Dec 10, 2017: Blueprint Medicines: Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood Disorder 66
Nov 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFR alpha Genotypes 67
Nov 01, 2017: Blueprint Medicines Announces Publication of BLU-285 Translational Data 70
Nov 01, 2017: Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting and Exposition 71
Sep 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma 72
Aug 21, 2017: Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference 74
Aug 02, 2017: Blueprint Medicines Provides Update on Clinical Program of its Cancer Drug, BLU-285 75
Aug 02, 2017: Blueprint Medicines Provides Update on Hepatocellular Carcinoma Drug BLU-554 76
Jun 05, 2017: Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mutation 77
May 17, 2017: Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting 79
Mar 20, 2017: Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667 80
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Blueprint Medicines Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Blueprint Medicines Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Blueprint Medicines Corp, Medical Devices Deals, 2012 to YTD 2018 10
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Blueprint Medicines Raises USD50 Million in Series C Venture Financing 13
Blueprint Medicines Raises US$25 Million In Series B Venture Financing 16
Blueprint Medicines Raises US$40 Million In Series A Venture Financing 18
Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 20
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 21
CStone Pharma Enters into Licensing Agreement with Blueprint Medicines 22
Roche Enters into Licensing Agreement with Blueprint Medicines 24
Blueprint Medicines Raises USD325.5 Million in Public Offering of Shares 26
Blueprint Medicines Raises USD230 Million in Public Offering of Shares 28
Blueprint Medicines Raises USD143.8 Million in Public Offering of Shares 30
Blueprint Medicines Completes IPO 32
Blueprint Medicines Corp, Key Competitors 34
Blueprint Medicines Corp, Key Employees 35
Blueprint Medicines Corp, Subsidiaries 36
List of Figures
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Blueprint Medicines Corp, Medical Devices Deals, 2012 to YTD 2018 10
【免責事項】
http://www.globalresearch.jp/disclaimer